Medytox said on the 1st that it has obtained marketing authorization for two hyaluronic acid (HA) fillers, "Neuramis," from Albania's National Agency for Medicines and Medical Devices (AKBPM) in Eastern Europe.
Medytox plans to further step up its push into Europe by successfully establishing "Neuramis Deep Lidocaine" and "Neuramis Volume Lidocaine" in Albania, a market with strong potential.
Neuramis is a hyaluronic acid filler independently developed by Medytox that has received the European Union's CE certification. For more than 10 years since launch, it has demonstrated efficacy and safety through numerous clinical data. By improving the efficiency of the hyaluronic acid cross-linking reaction, it enhanced durability, and by minimizing residual amounts of the cross-linker (BDDE), it reduced the likelihood of side effects such as swelling and inflammation. In Feb., it obtained marketing authorization in Serbia, accelerating its entry into the European market. Recently, beyond Europe, it has expanded into 35 countries in the Middle East, South America, and Asia.
A Medytox official said, "We will leverage the marketing know-how accumulated in Europe to speed up entry into the Albanian market," adding, "We will continue to develop overseas sales channels to further increase global market share."